Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia

Vaderis Therapeutics AG Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America Canada Europe Maryland

View original content:https://www.prnewswire.co.uk/news-releases/vaderis-receives-fda-fast-track-designation-for-vad044-for-the-treatment-of-hereditary-hemorrhagic-telangiectasia-302307364.html